L'intérêt à découvert pour Perspective Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Perspective Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Perspective Therapeutics (AMEX:CATX) Stock, Rapport sur les intérêts à découvert

Perspective Therapeutics

Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics Inc

Trading Ideas

UMAC

Unusual Machines Shares Halted On Circuit Breaker To The Downside, Stock Now Up 75.8%

Peloton Interactive's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NYSE">PTON</a>) short percent of float has fallen 7.42% since its last report. The company recently reported that it has 59.95 million shares sold short, which is 18.84% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.59 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Peloton Interactive Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732717822_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Peloton Interactive has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Peloton Interactive's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Peloton Interactive's peer group average for short interest as a percentage of float is 7.15%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

PTON

How Is The Market Feeling About Peloton Interactive?

Semtech's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NYSE">SMTC</a>) short percent of float has fallen 4.35% since its last report. The company recently reported that it has 6.55 million shares sold short, which is 11.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Semtech Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732717816_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Semtech has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Semtech's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Semtech's peer group average for short interest as a percentage of float is 10.40%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SMTC

Peering Into Semtech's Recent Short Interest

LPL Finl Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NYSE">LPLA</a>) short percent of float has risen 19.67% since its last report. The company recently reported that it has 1.08 million shares sold short, which is 1.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.29 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>LPL Finl Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732717811_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for LPL Finl Hldgs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing LPL Finl Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, LPL Finl Hldgs's peer group average for short interest as a percentage of float is 3.02%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

LPLA

How Is The Market Feeling About LPL Finl Hldgs?

Barclays analyst Tim Long maintains Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) with a Equal-Weight and raises the price target from $106 to $115.

News

Price Target

Analyst Ratings

DELL

Barclays Maintains Equal-Weight on Dell Technologies, Raises Price Target to $115

Outlook Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42210551/outlook-therapeutics-announces-preliminary-topline-results-of-norse-eight-clinical-trial" rel="noreferrer noopener">wet AMD patients</a>.
In the NORSE EIGHT trial, ONS-5010 did not meet the pre-specified noninferiority endpoint at week 8 set forth in the special protocol assessment (SPA) with the FDA.
The pre-specified noninferiority endpoint was measured by mean change in best corrected visual acuity (BCVA) from baseline to week 8.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37893076/why-is-eye-disease-focused-outlook-therapeutics-stock-trading-higher-on-friday" rel="noreferrer noopener">Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?</a>
The difference in the means between the ONS-5010 and Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Lucentis (ranibizumab) in the NORSE EIGHT trial was -2.257 BCVA letters, while the lower bound of the pre-specified noninferiority margin in the SPA was -3.5; the hypothesis of noninferiority was not met (p&gt;0.025).&nbsp;
In the intent-to-treat (ITT) primary dataset, NORSE EIGHT demonstrated a mean +4.2 letter improvement in BCVA in the ONS-5010 arm and +6.3 letter improvement in BCVA in the ranibizumab arm.
However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010.
Data analysis is ongoing as month 3 data from NORSE EIGHT are being collected. The data is expected to be available in January 2025.
Upon receipt of the full month 3 efficacy and safety results for NORSE EIGHT, Outlook Therapeutics plans to resubmit the U.S. marketing application for ONS-5010 in the first quarter of calendar 2025.
ONS-5010/Lytenava (bevacizumab gamma) has already been granted Marketing Authorization in the European Union and the U.K.
Outlook Therapeutics intends to continue efforts to launch in Europe in 2025, either directly or with a licensing partner.
If approved by the FDA, Outlook Therapeutics plans to commercialize ONS-5010/Lytenava (bevacizumab-vikg) directly in the U.S. It is also assessing partnering options for Lytenava (bevacizumab gamma) in Europe and other regions <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40706252/outlook-therapeutics-announces-completion-of-enrollment-in-norse-eight-clinical-trial" rel="noreferrer noopener">outside of the U.S.</a>
Price Action: OTLK stock is down 80% at $0.97 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42213279/whats-going-on-with-us-listed-chinese-stocks-alibaba-jd-nio-li-xpeng-on-wednesday-2" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With US Listed Chinese Stocks Alibaba, JD, Nio, Li, XPeng On Wednesday?</a></li>
</ul>
Photo by Amanda Dalbjörn on Unsplash.

Biotech

Equities

Health Care

Movers

General

OTLK

RHHBY

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

TD Cowen analyst Marc Bianchi reiterates TechnipFMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) with a Buy and maintains $37 price target.

Reiteration

TD Cowen Reiterates Buy on TechnipFMC, Maintains $37 Price Target

At the recent <a href="https://www.benzinga.com/fintech-awards">Benzinga Fintech Awards</a>, Sean Kozak, managing partner and CEO of Tickblaze, outlined a strategic push to expand the accessibility of advanced trading technology. Previously tailored to institutional clients, the company aims to bring its tools to retail traders, aligning with the event's focus on innovation in financial technology.
<h4 class="wp-block-heading">Bringing Institutional Tools to Retail Traders</h4>
Tickblaze, initially developed for institutional firms such as hedge funds and proprietary trading desks, is taking steps to introduce its technology to a broader audience. 
Kozak explained, "Our company was originally built for institutions, traders, and firms. We essentially evolved the technology to bring it mainstream retail."
See Also: <a href="https://www.benzinga.com/24/11/42210528/us-stock-futures-signal-a-muted-open-smallcaps-may-advance-analyst-flags-cross-asset-volatility">Major US Stock Futures Slide, Small-Caps Buck Trend: Market Strategist Flags This As The &#8216;Stronger Times Of The Year For Stocks&#8217;</a>
Using the event as a platform, Tickblaze showcased its vision for making institutional-grade trading tools available to the public, reflecting a shift in its mission to democratize advanced market solutions.
<h4 class="wp-block-heading">Partnerships and Collaboration Drive Expansion</h4>
Kozak emphasized the importance of partnerships in Tickblaze's growth strategy, describing discussions with brokers, institutional clients, and other fintech firms. "It is about our partnerships with brokers, institutional funds, and clients," he said, highlighting the collaborative opportunities present at the event.
The emphasis on partnerships extended beyond business deals, with Kozak focusing on solutions to address industry challenges. He noted the event's role in fostering collaboration: &#8220;This entire event is about B2B partnerships and finding synergy between different organizations."
<h4 class="wp-block-heading">A Launchpad for Future Growth</h4>
Tickblaze used its participation in the Benzinga Fintech Awards as a springboard for unveiling its retail-focused strategy. Kozak described the event as a pivotal moment for the company's journey, adding, "We strategically chose this event because we have a very similar vision to Benzinga, in that innovation should be accessible to everyone."
<h4 class="wp-block-heading">Looking Ahead</h4>
Kozak praised the event's ability to convene major names in the fintech community, describing it as essential for any company aiming to impact the industry. "It's the who's who crowd of the FinTech space," he said, reaffirming Tickblaze's commitment to participating in future Benzinga events.
The company's efforts to expand its audience reflect a broader mission to reshape the accessibility of trading tools. With a clear focus on collaboration and addressing the needs of both institutional and retail users, Tickblaze is positioning itself to lead in financial technology.
New Report:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42209900/microstrategy-surges-8-in-pre-market-trading-on-wednesday-whats-going-on">MicroStrategy Surges 8% In Wednesday Pre-Market: What&#8217;s Going On?</a></li>
</ul>
Image via Pexels

Fintech news covering the emerging Financial Technology services sector

Fintech

Events

Exclusives

Interview

From Hedge Funds To Retail: How Advanced Trading Platforms Are Going Mainstream

Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) just secured a <a href="https://www.benzinga.com/news/large-cap/24/11/42187787/intel-to-receive-nearly-8-billion-in-federal-funding-under-chips-act-for-us-expansion">$7.86 billion grant</a> under the CHIPS Act, marking a significant step in the Biden administration&#8217;s push to bolster domestic chip manufacturing.
But while this government lifeline aims to supercharge Intel's factory expansion, the struggling chip giant still faces formidable challenges as it tries to claw its way back to relevance.
<h2 class="wp-block-heading">A Much-Needed Boost For Intel</h2>
The CHIPS Act grant, slightly lower than the initial $8.5 billion promise, is part of Intel's strategy to expand its U.S. manufacturing footprint. CEO Pat Gelsinger hailed the funding as a pivotal moment for American semiconductor leadership, emphasizing Intel's commitment to ramping up operations. 
However, the trimmed award reflects growing skepticism about Intel's execution abilities amid a rocky year for the company.
Read Also: <a href="https://www.benzinga.com/24/11/42186138/taiwan-semis-growth-fuels-us-rise-to-second-in-chipmaking">Taiwan Semi&#8217;s Growth Fuels US Rise To Second In Chipmaking: Report</a>
<h2 class="wp-block-heading">Clouds Over Santa Clara</h2>
Despite the CHIPS windfall, Intel is grappling with heavy losses and strategic uncertainty. The company reported a $17 billion loss last quarter and has slashed 15,000 jobs as part of cost-cutting efforts. Recent moves, like considering the sale of a minority stake in <a href="https://www.benzinga.com/markets/equities/24/10/41395473/intel-reportedly-considers-selling-minority-stake-in-altera-unit-for-17b-amid-market-challenges-">its Altera business</a>, signal Intel's urgent need to stabilize finances.
Adding to the drama, rumors of a possible Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) <a href="https://www.benzinga.com/news/24/09/40968128/qualcomm-reportedly-eyes-potential-takeover-of-intel-amid-60-stock-decline-but-antitrust-concerns-lo">takeover have swirled</a>, underscoring Intel's precarious position in the chip market. 
<h2 class="wp-block-heading">Intel Stock Down 45%, Long Term Still Bearish</h2>
Intel's stock performance hasn't exactly inspired confidence, with shares down 45% over the past year. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27081448/Screenshot-2024-11-27-at-6.44.34-PM.png" alt="" class="wp-image-667314" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27081448/Screenshot-2024-11-27-at-6.44.34-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27081448/Screenshot-2024-11-27-at-6.44.34-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112724&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Recent technical indicators paint a picture of indecision:
<ul>
<li>Bearish Trends: Intel's share price of $23.90 sits below its eight-day ($24.35) and 20-day ($24.32) simple moving averages (SMAs), flashing bearish signals.</li>
<li>Bullish Glimmers: The 50-day SMA of $23.39 and a moving average convergence/divergence (MACD) of 0.32 suggest potential short-term gains.</li>
<li>Long-Term Pain: The 200-day SMA of $29.98 highlights a steep climb ahead.</li>
</ul>
While the CHIPS Act grant provides a much-needed boost, Intel's turnaround hinges on its ability to execute on its manufacturing goals and navigate a volatile market. 
Investors, wary of its recent missteps, may need more than government funding to restore their faith in the Silicon Valley stalwart. For now, Intel remains a high-risk, high-reward play in an increasingly competitive chip landscape.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42193158/amds-downward-spiral-is-a-reversal-on-the-horizon-or-just-a-blip">AMD Struggles Below Critical Levels: Can Market Share Growth Turn The Tide?</a></li>
</ul>
Photo: Tada Images/Shutterstock.com

Long Ideas

Technicals

Tech

INTC

QCOM

Intel Secures $7.86 Billion Grant, But Technical Signals Flash Warnings

Contracts

Haoxi Health Technology Wins RMB30M Framework Contract To Provide Digital Advertising Services For Tengyuan Media Advertising

TD Cowen analyst Oliver Chen maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a Hold and lowers the price target from $20 to $16.

TD Cowen Maintains Hold on Kohl's, Lowers Price Target to $16

B of A Securities analyst Lorraine Hutchinson maintains Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) with a Underperform and raises the price target from $20 to $22.

B of A Securities Maintains Underperform on Nordstrom, Raises Price Target to $22

Analysts on Monday drew parallels between Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) recent performance and its infamous "Thanksgiving Day Massacre" in 2020, when prices dropped sharply before rebounding <a href="https://www.benzinga.com/money/bitcoin-price-prediction">to new highs</a>.
What Happened: Coinbureau co-founder Nic Puckrin on X <a href="https://x.com/nicrypto/status/1861661962116923470">highlighted</a> that Bitcoin has fallen from just below $100,000 to $91,500 this week, a less severe 8% decline compared to the 17% drop in 2020 from Nov 25 to Nov 27.
In 2020, Bitcoin&#8217;s sharp decline set the stage for a sustained rally. 
For 2024, factors like institutional interest from entities like <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42165734/bitcoin-etfs-registered-record-312-billion-net-inflows-last-week">BlackRock and ETFs</a>, alongside macroeconomic variables such as <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42198763/fed-minutes-reveal-confidence-in-inflation-reduction-yet-flag-divergent-views-on-interest-rate-path-ahead">inflation and interest rates</a>, play a larger role in shaping the market outlook.
Puckrin noted that on-chain data reveals whales are accumulating Bitcoin, signaling a potential rebound. 
Still, the broader market awaits confirmation of whether retail investors will join or if a deeper correction looms.
Puckrin himself views Thanksgiving dips as moments tied to volatility but often "turning points for new highs." 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42197276/anthony-scaramucci-trump-win-is-the-greatest-political-comeback-in-us-history-crypto-surge-following-it-was-3-years-overdue">Anthony Scaramucci: Trump Win Is &#8216;The Greatest Political Comeback In US History,&#8217; Crypto Surge Following It Was 3 Years Overdue</a>
Galaxy&#8217;s Head of Research, Alex Thorn, echoed this sentiment, reminding traders of Bitcoin's 2020 Thanksgiving dip, which was followed by a tripling of its price over the next five months.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">who remembers the thanksgiving dump of 2020? bitcoin dumped 17% between wednesday nov 25 and friday nov 27, 2020 btcusd later went on to more than 3x over the next 5 months. does history rhyme? <a href="https://t.co/y2bWV23P9n">pic.twitter.com/y2bWV23P9n</a>
&mdash; Alex Thorn (@intangiblecoins) <a href="https://twitter.com/intangiblecoins/status/1861605206556922055?ref_src=twsrc%5Etfw">November 27, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Recent Santiment data highlighted a dip in social sentiment for major cryptocurrencies like Bitcoin, Ethereum and Solana, which may weigh on <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42163156/why-bitcoins-rally-is-stalling-below-100000">Bitcoin stalling below $100,000.</a>
Standard Chartered&#8217;s analysts anticipate a potential correction, identifying $85,000 to $88,700 as critical support zones before an uptrend resumes.
The bank&#8217;s forecast for Bitcoin includes a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42192364/bitcoin-correction-could-go-as-deep-as-88700-but-125000-year-end-target-remains-in-play-says-standard-chartered">year-end target of $125,000</a> and $200,000 by the end of 2025. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42191142/bitcoin-is-being-sold-into-a-market-with-ample-demand-from-institutions-says-marathon-ceo-fred-thiel">Bitcoin Is Being Sold Into A Market With &#8216;Ample Demand&#8217; From Institutions, Says Marathon CEO Fred Thiel</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin's 2020 'Thanksgiving Massacre' To Repeat Or Is The Holiday A 'Turning Point For New Highs'?

B of A Securities analyst Lorraine Hutchinson maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Buy and raises the price target from $46 to $53.

URBN

B of A Securities Maintains Buy on Urban Outfitters, Raises Price Target to $53

GOEV

Canoo Announced Issuance Of 7,185,125 Shares At $0.3992 Each To Vendors For Services Rendered

Starting April 2025, patients suffering from chronic pain will have greater access to medical marijuana, according to a new decree from the Ministry of Health. Under the expanded access, general practitioners (GPs) in the country will be allowed to prescribe medical marijuana to registered patients with chronic pain, <a href="https://www.expats.cz/czech-news/article/czechia-takes-step-towards-laxer-cannabis-laws-with-new-bill">writes</a> Expats.
Ministry spokesperson Ondřej Jakob <a href="https://www.novinky.cz/clanek/domaci-ministerstvo-ustupuje-poptavce-po-konopi-na-bolest-ho-nove-predepisou-i-praktici-40498698">confirmed </a>to news outlets Novinky and Právo that the new rules are designed to simplify access."The decree allows GPs to prescribe medicinal cannabis for chronic, intractable pain."
Under the current law, only specialized doctors can prescribe cannabis, which is limiting for many patients. According to official data, roughly 8,000 people in the country use cannabis legally, but the demand is much higher. The National Drug Monitoring Center recently revealed results of its survey showing that about 600,000 Czechs use medical marijuana, and more than a million have tried it for self-treatment this year.
"It doesn't make sense that we can prescribe strong opiates like morphine but not medical cannabis," Dr. Petr Šonka, chairman of the Czech Association of General Practitioners, told Novinky. Šonka further stressed the importance of managing pain for terminal patients.
Furthermore, under the new rules, prescriptions will be valid for up to three months, and insurance will still cover 90% of the expense for up to 30 grams of marijuana per month. Coverage for cannabis extracts will also be expanded.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41890759/polish-parliamentary-committee-sends-cannabis-decriminalization-petition-to-prime-minister">Polish Parliamentary Committee Sends Cannabis Decriminalization Petition To Prime Minister</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Proposal To Allow Cultivation And Possession</h2>
The expanded medical marijuana access follows up on the Czech <a href="https://www.benzinga.com/markets/cannabis/24/11/42043465/czech-government-legalizes-cultivation-of-three-cannabis-plants-allows-possession-of-50-grams">government's proposal</a> of a draft law that would reform&nbsp;criminal law regarding cannabis, with changes including relaxed rules on&nbsp;home cultivation and possession. The draft law now needs to be viewed by both chambers of Parliament.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41295350/czech-senate-approves-restrictions-on-sale-of-kratom-and-hhc-products">Czech Senate Approves Restrictions On Sale Of Kratom And HHC Products</a></li>
</ul>
Photo: Benzinga edit with images by <a href="https://www.pexels.com/@rdne/">RDNE Stock project</a> and <a href="https://www.pexels.com/@jules-clark-624979041/">Jules Clark</a> via Pexels

Cannabis

Czech General Practitioners To Prescribe Medical Marijuana For Chronic Pain With Insurance Coverage Starting 2025

TD Cowen analyst Andrew Kligerman maintains Axis Capital Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXS#NYSE">AXS</a>) with a Buy and raises the price target from $118 to $127.

TD Cowen Maintains Buy on Axis Capital Holdings, Raises Price Target to $127

<ul>
<li>KODK</li>
<li>NVDA</li>
<li>MSTR</li>
<li>ACHR</li>
<li>DELL</li>
<li>RKLB</li>
<li>TSLA</li>
<li>CORN</li>
<li>AMZN</li>
<li>LOT</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment" title="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>

ACHR

AMZN

CORN

KODK

MSTR

NVDA

RKLB

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 27, 2024 (Via Swaggy Stocks)

B of A Securities analyst Vivek Arya maintains Ambarella (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) with a Underperform and raises the price target from $57 to $65.

AMBA

B of A Securities Maintains Underperform on Ambarella, Raises Price Target to $65

In the current session, the stock is trading at $22.09, after a 0.41% increase. Over the past month, Ares Capital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>) stock increased by 3.09%, and in the past year, by 11.00%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732716911_0.png" alt="Past Year Chart" />

<h3>Ares Capital P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Ares Capital has a lower P/E than the aggregate P/E of 46.03 of the Capital Markets industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732716911_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

ARCC

A Look Into Ares Capital Inc's Price Over Earnings

09:43 EST Perspective Therapeutics (CATX) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-tim...

Perspective Therapeutics Inc trading halted, volatility trading pause

Anshul Dhankher, an analyst from LifeSci Capital, maintained the Buy rating on Perspective Therapeutics (CATX – Research Report). The associated pr...

Promising Potential in Perspective Therapeutics' VMT-alpha-NET Program Amid Market Hesitations

In a report released today, Justin Walsh from JonesTrading reiterated a Buy rating on Perspective Therapeutics (CATX – Research Report), with a pri...

Cautious Optimism: Justin Walsh's Buy Rating on Perspective Therapeutics Amidst Mixed Trial Results

JonesResearch analyst Justin Walsh views the selloff in shares Perspective Therapeutics (CATX) yesterday after the company reported initial results...

Perspective Therapeutics selloff a buying opportunity, says JonesResearch

Truist Financial analyst Nicole Germino assigned a Buy rating to Perspective Therapeutics (CATX – Research Report) today and set a price target of ...

Truist Financial Releases a Buy Rating on Perspective Therapeutics (CATX)

Oppenheimer lowered the firm's price target on Perspective Therapeutics (CATX) to $16 from $22 and keeps an Outperform rating on the shares. The fi...

Perspective Therapeutics price target lowered to $16 from $22 at Oppenheimer

In a report released on November 22, Alec Stranahan from Bank of America Securities downgraded Perspective Therapeutics (CATX – Research Report) to...

Cautious Hold Rating for Perspective Therapeutics Amid Efficacy and Safety Concerns

In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on Perspective Therapeutics (CATX – Research Report). The compan...

RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)

BofA analyst Alec Stranahan downgraded Perspective Therapeutics (CATX) to Neutral from Buy with a price target of $6, down from $24, after the comp...

Perspective Therapeutics downgraded to Neutral from Buy at BofA

B. Riley lowered the firm's price target on Perspective Therapeutics (CATX) to $9 from $17 and keeps a Buy rating on the shares. After taking anoth...

Perspective Therapeutics price target lowered to $9 from $17 at B. Riley

CATX

Press Releases

Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results

Earnings

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Comments

Perspective Therapeutics

Intérêt court

Perspective Therapeutics (AMEX:CATX) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL